Global health crises, with the COVID-19 pandemic being the most predominant one, revealed the importance and the stark inefficiencies of traditional drug development pathways.
With a certificate from the China National Drug Administration, Illumina has begun encouraging more clinical laboratories to choose the MiSeqDx system to develop new clinical assays.